Abstract
Apoptosis of T-lymphocytes is a fundamental process regulating antigen receptor repertoire selection during T cell maturation and homeostasis of the immune system. It also plays a key role in elimination of autoreactive lymphocytes. Resting mature T cells are activated by antigen to elicit an appropriate immune response. In contrast, preactivated T cells undergo activation-induced cell death (AICD) in response to TCR triggering alone. Thus, death by apoptosis is essential for function, growth and differentiation of T-lymphocytes. This review focuses on apoptosis mechanisms involved in T cell development and during the course of an immune response.
Keywords: T cell Apoptosis, Immune Response, CD95 SIGNALING PATHWAY, THYMOCYTE SELECTION, DEATH RECEPTORS, Death domain, FLICE inhibitory protein
Current Molecular Medicine
Title: Regulation of T cell Apoptosis during the Immune Response
Volume: 2 Issue: 3
Author(s): Sven Baumann, Andreas Krueger, Sabine Kirchhoff and Peter H. Krammer
Affiliation:
Keywords: T cell Apoptosis, Immune Response, CD95 SIGNALING PATHWAY, THYMOCYTE SELECTION, DEATH RECEPTORS, Death domain, FLICE inhibitory protein
Abstract: Apoptosis of T-lymphocytes is a fundamental process regulating antigen receptor repertoire selection during T cell maturation and homeostasis of the immune system. It also plays a key role in elimination of autoreactive lymphocytes. Resting mature T cells are activated by antigen to elicit an appropriate immune response. In contrast, preactivated T cells undergo activation-induced cell death (AICD) in response to TCR triggering alone. Thus, death by apoptosis is essential for function, growth and differentiation of T-lymphocytes. This review focuses on apoptosis mechanisms involved in T cell development and during the course of an immune response.
Export Options
About this article
Cite this article as:
Baumann Sven, Krueger Andreas, Kirchhoff Sabine and Krammer H. Peter, Regulation of T cell Apoptosis during the Immune Response, Current Molecular Medicine 2002; 2 (3) . https://dx.doi.org/10.2174/1566524024605671
DOI https://dx.doi.org/10.2174/1566524024605671 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Genetics of Alzheimer's Disease and Frontotemporal Dementia
Current Molecular Medicine Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.
Current Topics in Medicinal Chemistry Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Phytoecdysteroids - From Isolation to Their Effects on Humans
Current Medicinal Chemistry The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Contribution of Specific Transport Systems to Anthracycline Transport in Tumor and Normal Cells
Current Drug Metabolism FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia
Current Pharmaceutical Design